Terray Therapeutics, a chemistry-first, AI-native biotech company, has unveiled EMMI, a next-generation AI platform designed to revolutionize de novo small molecule drug discovery. EMMI, which stands for Experimentation Meets Machine Intelligence, integrates Terray’s proprietary ultra-miniaturized lab hardware with a full-stack AI system to accelerate and optimize the entire drug discovery process. At the core of EMMI is COATI3, Terray’s third-generation chemistry foundation model, trained on over a billion diverse molecules. Unlike traditional molecular representations that lose meaning when manipulated, COATI3 encodes molecules in a mathematical latent space, creating a powerful, interpretable language for AI. This enables the platform to generate, predict, and select molecules with unprecedented accuracy and efficiency. EMMI’s workflow is built around three key AI components. First, the Generate model uses advanced generative techniques, including a novel reinforcement learning-based method with a policy gradient algorithm, to design millions of potential molecules in each cycle—prioritizing those that are not only effective but also synthetically feasible. Second, the Predict model rapidly evaluates these candidates for potency, selectivity, and key drug-like properties such as solubility, LogD, permeability, and metabolic stability. This is made possible by Terray’s high-speed, high-precision data infrastructure, which has already generated over 13 billion target-molecule interaction measurements. Finally, the new Select model uses AI to determine the optimal number and type of molecules to test next, based on prediction uncertainty and expected impact. This step dramatically reduces trial and error, cutting both time and cost by up to three times compared to industry-standard methods. The platform’s power is amplified by Terray’s unique data advantage. Its ultra-dense microarray technology produces more than 1 billion new measurements per quarter, creating a rich, high-quality dataset that allows EMMI to explore the "dark matter" of chemical space—areas where no known starting points exist. This has enabled Terray to identify structurally novel molecules for every program, even for previously intractable targets. EMMI is already driving progress across Terray’s internal pipeline, which focuses on immunology, and in partnerships spanning multiple therapeutic areas. The platform is not static—its models continuously improve through real-world feedback from experiments, creating a self-optimizing, closed-loop system. “EMMI is a platform we have purpose built to solve some of the hardest challenges in drug discovery,” said Jacob Berlin, Ph.D., CEO of Terray Therapeutics. “With EMMI, we’re not just finding molecules—we’re redefining how we discover them, turning what was once impossible into inevitable.” Narbe Mardirossian, Chief Technology Officer, added, “We’re excited by what EMMI can do today, but even more so by what it will become. As we learn from every experiment, the platform evolves, moving us closer to a future where AI and human ingenuity work in perfect synergy to deliver life-changing medicines.”